Polatuzumab vedotin


  • Active Substance: Polatuzumab vedotin
  • Name: Polivy
  • Therapeutic area: Diffuse large B-cell lymphoma (DLBCL) 
  • Pharmaceutical company: Roche Pharma AG


Time table:

  • Publication of project plan: 22.11.2019
  • Publication of final assessment expected: 13.02.2020


Assessment information:

  • Title: Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) 
  • Author/Co-Author: IQWiG (Germany), HAS (France)
  • Dedicated Reviewers: FIMEA (Finland), SUKL (Czech Republic), TLV (Sweden), INFARMED (Portugal)
  • Observer: GBA (Germany)

› G-BA assessment available (D-507)